Physician profile
Charles D Webb
NPI 1982675658
$826.97
in general payments reported to CMS, 2019-2025
26 companies · $16.91 in 2025
The $16.91 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.41 · 2020: $33.82 · 2021: $109 · 2022: $145 · 2023: $283 · 2024: $142 · 2025: $16.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $128.82 | 2022-2025 | |
| Celgene Corporation | $126.66 | 2021-2023 | Reblozyl, Pomalyst |
| Amgen INC. | $53.10 | 2019-2023 | Lumakras |
| Foundation Medicine, INC. | $44.88 | 2019 | |
| Pfizer INC. | $36.95 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $35.03 | 2021-2024 | Libtayo |
| Glaxosmithkline, LLC. | $34.96 | 2021-2024 | Ojjaara |
| Abbvie INC. | $33.78 | 2024 | |
| Novo Nordisk INC | $32.10 | 2023 | |
| Merck Sharp & Dohme LLC | $25.68 | 2019-2022 | |
| Tosoh Bioscience, INC. | $25.00 | 2019 | |
| Daiichi Sankyo INC. | $21.66 | 2023 | Enhertu |
| Genmab U.S., INC. | $20.81 | 2021 | |
| Sun Pharmaceutical Industries INC. | $20.72 | 2023 | Yonsa, Odomzo |
| Taiho Oncology, INC. | $19.88 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $17.65 | 2022 | |
| Apellis Pharmaceuticals, INC. | $17.29 | 2023 | Empaveli |
| Grifols USA, LLC | $17.07 | 2020 | |
| Stemline Therapeutics INC. | $16.75 | 2020 | |
| Genentech USA, INC. | $16.55 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.16 | 2021 | |
| Pharmacosmos Therapeutics INC. | $14.17 | 2023 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $13.78 | 2024 | Opdivo |
| Mirati Therapeutics, INC. | $13.70 | 2023 | Krazati |
| Seagen INC. | $13.48 | 2022 | |
| Janssen Biotech, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.